Should you have a PSA test for Prostate Cancer?

At my age, I have had a number of friends who have been diagnosed with prostate cancer, and some after further tests have found that did not actually had the disease and I wondered why. Many of my friends were given a PSA test by their doctor. I found out that this test is not as reliable as one may think. The information below is from the Canadian Task Force on Preventative Health. They do not recommend the PSA be used for screening for Prostate cancer. However, each of is unique and I would recommend that you talk to your doctor about this test.

The PSA test is a blood test that is commonly used to detect possible prostate cancer. Elevated PSA levels may indicate the presence of prostate cancer, but can also be caused by other common non-cancer related conditions such as an enlarged prostate (also known as benign prostatic hyperplasia or BPH) or inflammation of the prostate gland (also known as prostatitis) due to an infection or other cause.

 2. Why does the CTFPHC recommend against PSA screening for prostate cancer?

The CTFPHC recommends against PSA screening because they found that the potential harms of screening outweigh the benefits.

3. Are there any other tests that can detect prostate cancer?

Currently

no other screening tests have been proven to accurately identify prostate cancer. Several tests are being developed to improve the accuracy of PSA screening. However, right now there is not enough evidence to tell us whether or not they are accurate.

4. Why are there harms with PSA screening? Isn't it a simple blood test?

The PSA test is a simple blood test, but if the result is positive, men are likely to then undergo further tests such as a biopsy. There are several harms associated with biopsies, as described below. In addition, there is a risk that you will be diagnosed and treated for

a slow-growing

cancer that would not have caused any trouble in your lifetime.

5. What if I still want the PSA test?

Because of recent efforts to encourage screening for prostate cancer, some men may still be interested in the test. Talk to your doctor about the benefits and harms of PSA screening.

There is a benefit of having PSA screening. The benefit is a lower risk of dying from prostate cancer

1 out of every 1,000 men will escape death from prostate cancer because they were screened with PSA.

However, the task force sees the following harms with having PSA screening

False-positive results

Most men who have a positive PSA result will undergo a prostate biopsy.

A false-positive result occurs when a man with a positive PSA result undergoes a biopsy, with the biopsy showing that he does not have prostate cancer.

178 out of every 1,000 men screened with the PSA test will have an unnecessary biopsy to confirm they do not have prostate cancer.

Complications of prostate biopsy

Prostate

biopsy carries a number of complications, including blood in the urine or semen, rectal bleeding, infection and in rare cases, death.

· 21 out of every 1,000 men who undergo prostate biopsy will have complications severe enough to require hospitalization.

· 2 out of every 1,000 men who undergo prostate biopsy will die within 120 days of the biopsy, because of complications.

Over diagnosis

Over diagnosis is the detection of cancers that grow so slowly they would not have caused illness or death during the man’s lifetime.

Almost half of all the cancers detected through PSA screening would not have caused illness or death in the man’s lifetime. However, because of uncertainty about whether their cancer would progress, most men will choose treatment and may experience complications of treatment.

Harms of treatment

For every 1,000 men who receive treatment for prostate cancer:

· 114–214 will have short-term complications such as infections, additional surgeries, and blood transfusions

· 127–442 will experience long-term erectile dysfunction

· up to 178 will experience long-term urinary incontinence

· 4 or 5 will die from complications of prostate cancer surgery

Statistics related to benefits and harms were calculated from the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the prostate cancer screening review.

"